We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$133B
1-Year Est. Return
43.5%
This Fund
S&P 500
This Quarter
Est. Return
+26.39%
1 Year Est. Return
+43.5%
3 Year Est. Return
+132.19%
5 Year Est. Return
+175.35%
10 Year Est. Return
+672.4%
AUM
$133B
AUM Growth
+$15.7B
(+13%)
Cap. Flow
-$1.75B
Cap. Flow
% of AUM
-1.32%
Top 10 Holdings %
Top 10 Hldgs %
30.35%
Holding
4,370
New
224
Increased
1,883
Reduced
1,827
Closed
182
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marvell Technology
MRVL
|
+$117M |
| 2 |
HONA
Honeywell Aerospace
HONA
|
+$117M |
| 3 |
SPCX
SpaceX
SPCX
|
+$100M |
| 4 |
P
Everpure Inc
P
|
+$67.3M |
| 5 |
Roku
ROKU
|
+$53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$212M |
| 2 |
Microsoft
MSFT
|
+$156M |
| 3 |
Amazon
AMZN
|
+$142M |
| 4 |
Honeywell
HON
|
+$119M |
| 5 |
NVIDIA
NVDA
|
+$94.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.1% |
| 2 | Financials | 11.93% |
| 3 | Industrials | 10.35% |
| 4 | Consumer Discretionary | 9.64% |
| 5 | Healthcare | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Pacira BioSciences
PCRX
$1B
| $2.51M | ﹤0.01% |
99,066
-23,849
| -19% | -$564K |
|
|
INVX
1802
Innovex International
INVX
$1.99B
| $2.51M | ﹤0.01% |
101,314
-12,283
| -11% | -$334K |
|
1803
Unitil
UTL
$930M
| $2.5M | ﹤0.01% |
47,475
-6,122
| -11% | -$318K |
|
1804
Concentrix
CNXC
$1.65B
| $2.5M | ﹤0.01% |
111,617
-4,271
| -4% | -$111K |
|
1805
Apogee Enterprises
APOG
$775M
| $2.5M | ﹤0.01% |
54,571
-8,438
| -13% | -$315K |
|
1806
Middlesex Water
MSEX
$1.01B
| $2.49M | ﹤0.01% |
44,402
-7,698
| -15% | -$405K |
|
1807
Itaú Unibanco
ITUB
$89.4B
| $2.49M | ﹤0.01% |
304,854
+8,377
| +3% | +$69.4K |
|
1808
PACS Group
PACS
$6.54B
| $2.49M | ﹤0.01% |
58,403
+4,769
| +9% | +$171K |
|
1809
Stoke Therapeutics
STOK
$1.6B
| $2.48M | ﹤0.01% |
75,931
+8,616
| +13% | +$277K |
|
1810
Southside Bancshares
SBSI
$927M
| $2.48M | ﹤0.01% |
70,585
-9,987
| -12% | -$331K |
|
1811
Eos Energy Enterprises
EOSE
$1.15B
| $2.48M | ﹤0.01% |
421,554
+56,023
| +15% | +$390K |
|
|
CSR
1812
Centerspace
CSR
$929M
| $2.48M | ﹤0.01% |
44,086
-4,599
| -9% | -$290K |
|
1813
Tandem Diabetes Care
TNDM
$1.09B
| $2.48M | ﹤0.01% |
164,053
-22,263
| -12% | -$389K |
|
1814
Iovance Biotherapeutics
IOVA
$4.98B
| $2.47M | ﹤0.01% |
594,164
+74,034
| +14% | +$281K |
|
1815
Trevi Therapeutics
TRVI
$2.05B
| $2.47M | ﹤0.01% |
132,463
+23,402
| +21% | +$340K |
|
1816
Scholastic
SCHL
$604M
| $2.46M | ﹤0.01% |
53,396
-20,612
| -28% | -$846K |
|
1817
F&G Annuities & Life
FG
$2.9B
| $2.46M | ﹤0.01% |
92,365
+44,945
| +95% | +$1.23M |
|
1818
Babcock & Wilcox
BW
$934M
| $2.45M | ﹤0.01% |
+173,936
| New | +$2.95M |
|
1819
Biohaven
BHVN
$1.96B
| $2.45M | ﹤0.01% |
164,749
+27,866
| +20% | +$300K |
|
1820
IMAX
IMAX
$3.07B
| $2.45M | ﹤0.01% |
61,377
+6,638
| +12% | +$254K |
|
1821
Butterfly Network
BFLY
$2.5B
| $2.44M | ﹤0.01% |
290,307
+35,964
| +14% | +$186K |
|
1822
LG Display
LPL
$2.98B
| $2.44M | ﹤0.01% |
626,765
+236,862
| +61% | +$1.09M |
|
1823
Vanguard Morningstar Small-Cap ETF
VB
$78.2B
| $2.43M | ﹤0.01% |
8,015
-5,934
| -43% | -$1.7M |
|
1824
Sony
SONY
$138B
| $2.42M | ﹤0.01% |
120,403
+7,825
| +7% | +$165K |
|
1825
Huntsman Corp
HUN
$1.56B
| $2.41M | ﹤0.01% |
226,924
+72,425
| +47% | +$998K |
|
Similar funds
RhumbLine Advisers's Q2 2026 Portfolio in Review
As of Q2 2026, RhumbLine Advisers held 4,370 positions worth $133B, up 13% from $117B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
RhumbLine Advisers's Q2 2026 filing shows 224 new, 1,883 increased, 1,827 reduced and 182 closed positions. Its largest new stake was Honeywell Aerospace: 529,091 shares worth $117M. The largest sale was Apple, an estimated $212M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 31% a quarter earlier, followed by Financials and Industrials.
- RhumbLine Advisers's largest Q2 2026 buy was Honeywell Aerospace: 529,091 shares worth $117M.
- RhumbLine Advisers added most to Marvell Technology in Q2 2026, an estimated $117M increase.
- RhumbLine Advisers's biggest Q2 2026 reduction was Apple, cutting an estimated $212M.
- RhumbLine Advisers fully exited Coterra Energy in Q2 2026, selling an estimated $53.5M.
- RhumbLine Advisers's ten largest holdings make up 30% of its $133B portfolio in Q2 2026.
- RhumbLine Advisers opened 224 new positions and closed 182 in Q2 2026.
- RhumbLine Advisers's portfolio value rose 13% quarter-over-quarter to $133B.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.